ClinicalTrials.gg
Drug

MLN 8237 clinical trials

Also written Alisertib and MLN8237.

studies test it
59
open now
4
in phase 3
1
first study started
2007

How each study uses MLN 8237 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the MLN 8237 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Aurora A Kinase Inhibitor MLN8237
17
PB-8237
3

Development codes

MLN8237
49

Other names

Alisertib
50

Studies by the year they started

59 studies that test it; most in 2013 (13)

Studies that test MLN 8237, by start year
YearStudies
20072
20082
20094
20103
20114
20128
201313
20146
20158
20161
20171
20191
20202
20242
20262

Who runs them

Industry 24 · Other 35

Millennium Pharmaceuticals, Inc. (20) · National Cancer Institute (NCI) (7) · Mayo Clinic (3) · M.D. Anderson Cancer Center (3) · Puma Biotechnology, Inc. (3) · Sidney Kimmel Cancer Center at Thomas Jefferson University (2) · Children's Oncology Group (2) · Massachusetts General Hospital (2)

Often tested with

Tested in the same studies.

Sapanisertib (1) · Romidepsin (1) · Cetuximab (1) · Rituximab (1) · Paclitaxel (1) · Hormone Therapy (1) · TAK 733 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test MLN 8237.

Studies

Open first, then newest update. How each study uses MLN 8237 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 59

See all 59 studies that test MLN 8237 →

Given beside what is tested · 5 — MLN 8237 is usual care or a partner of the new treatment